Literature DB >> 30700606

An Epigenetic Journey: Epstein-Barr Virus Transcribes Chromatinized and Subsequently Unchromatinized Templates during Its Lytic Cycle.

Adityarup Chakravorty1, Bill Sugden2, Eric C Johannsen3,2.   

Abstract

The Epstein-Barr virus (EBV) lytic phase, like those of all herpesviruses, proceeds via an orderly cascade that integrates DNA replication and gene expression. EBV early genes are expressed independently of viral DNA amplification, and several early gene products facilitate DNA amplification. On the other hand, EBV late genes are defined by their dependence on viral DNA replication for expression. Recently, a set of orthologous genes found in beta- and gammaherpesviruses have been determined to encode a viral preinitiation complex (vPIC) that mediates late gene expression. The EBV vPIC requires an origin of lytic replication in cis, implying that the vPIC mediates transcription from newly replicated DNA. In agreement with this implication, EBV late gene mRNAs localize to replication factories. Notably, these factories exclude canonical histones. In this review, we compare and contrast the mechanisms and epigenetics of EBV early and late gene expression. We summarize recent findings, propose a model explaining the dependence of EBV late gene expression on lytic DNA amplification, and suggest some directions for future study.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  DNA methylation; Epstein-Barr virus; chromatin; epigenetics; herpesviruses; histones; transcription

Mesh:

Substances:

Year:  2019        PMID: 30700606      PMCID: PMC6450099          DOI: 10.1128/JVI.02247-18

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  92 in total

1.  A functionally distinct TATA box required for late progression through the Epstein-Barr virus life cycle.

Authors:  T R Serio; N Cahill; M E Prout; G Miller
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

2.  Viral DNA synthesis is required for the efficient expression of specific herpes simplex virus type 1 mRNA species.

Authors:  L E Holland; K P Anderson; C Shipman; E K Wagner
Journal:  Virology       Date:  1980-02       Impact factor: 3.616

Review 3.  Structure and functions of powerful transactivators: VP16, MyoD and FoxA.

Authors:  Hiroyuki Hirai; Tetsuya Tani; Nobuaki Kikyo
Journal:  Int J Dev Biol       Date:  2010       Impact factor: 2.203

4.  Lytic infection of permissive cells with human cytomegalovirus is regulated by an intrinsic 'pre-immediate-early' repression of viral gene expression mediated by histone post-translational modification.

Authors:  Ian J Groves; Matthew B Reeves; John H Sinclair
Journal:  J Gen Virol       Date:  2009-06-10       Impact factor: 3.891

5.  Requirement of a 12-base-pair TATT-containing sequence and viral lytic DNA replication in activation of the Kaposi's sarcoma-associated herpesvirus K8.1 late promoter.

Authors:  Shuang Tang; Koji Yamanegi; Zhi-Ming Zheng
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

6.  Both Epstein-Barr virus (EBV)-encoded trans-acting factors, EB1 and EB2, are required to activate transcription from an EBV early promoter.

Authors:  A Chevallier-Greco; E Manet; P Chavrier; C Mosnier; J Daillie; A Sergeant
Journal:  EMBO J       Date:  1986-12-01       Impact factor: 11.598

7.  EBV latency types adopt alternative chromatin conformations.

Authors:  Italo Tempera; Michael Klichinsky; Paul M Lieberman
Journal:  PLoS Pathog       Date:  2011-07-28       Impact factor: 6.823

Review 8.  Epstein-Barr virus lytic reactivation regulation and its pathogenic role in carcinogenesis.

Authors:  Hongde Li; Sufang Liu; Jianmin Hu; Xiangjian Luo; Namei Li; Ann M Bode; Ya Cao
Journal:  Int J Biol Sci       Date:  2016-10-18       Impact factor: 6.580

9.  Methylation-dependent binding of the epstein-barr virus BZLF1 protein to viral promoters.

Authors:  Sarah J Dickerson; Yongna Xing; Amanda R Robinson; William T Seaman; Henri Gruffat; Shannon C Kenney
Journal:  PLoS Pathog       Date:  2009-03-27       Impact factor: 6.823

10.  A Temporal Proteomic Map of Epstein-Barr Virus Lytic Replication in B Cells.

Authors:  Ina Ersing; Luis Nobre; Liang Wei Wang; Lior Soday; Yijie Ma; Joao A Paulo; Yohei Narita; Camille W Ashbaugh; Chang Jiang; Nicholas E Grayson; Elliott Kieff; Steven P Gygi; Michael P Weekes; Benjamin E Gewurz
Journal:  Cell Rep       Date:  2017-05-16       Impact factor: 9.423

View more
  14 in total

1.  Conserved CxnC Motifs in Kaposi's Sarcoma-Associated Herpesvirus ORF66 Are Required for Viral Late Gene Expression and Are Essential for Its Interaction with ORF34.

Authors:  Allison L Didychuk; Angelica F Castañeda; Lola O Kushnir; Carolyn J Huang; Britt A Glaunsinger
Journal:  J Virol       Date:  2020-01-06       Impact factor: 5.103

2.  Pharmacologic Activation of Lytic Epstein-Barr Virus Gene Expression without Virion Production.

Authors:  Jaeyeun Lee; John G Kosowicz; S Diane Hayward; Prashant Desai; Jennifer Stone; Jae Myun Lee; Jun O Liu; Richard F Ambinder
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

3.  Comprehensive Analyses of Intraviral Epstein-Barr Virus Protein-Protein Interactions Hint Central Role of BLRF2 in the Tegument Network.

Authors:  Yuya Hara; Takahiro Watanabe; Masahiro Yoshida; H M Abdullah Al Masud; Hiromichi Kato; Tomohiro Kondo; Reiji Suzuki; Shutaro Kurose; Md Kamal Uddin; Masataka Arata; Shouhei Miyagi; Yusuke Yanagi; Yoshitaka Sato; Hiroshi Kimura; Takayuki Murata
Journal:  J Virol       Date:  2022-07-11       Impact factor: 6.549

4.  Methionine metabolism controls the B cell EBV epigenome and viral latency.

Authors:  Rui Guo; Jin Hua Liang; Yuchen Zhang; Michael Lutchenkov; Zhixuan Li; Yin Wang; Vicenta Trujillo-Alonso; Rishi Puri; Lisa Giulino-Roth; Benjamin E Gewurz
Journal:  Cell Metab       Date:  2022-09-06       Impact factor: 31.373

Review 5.  Control of Viral Latency by Episome Maintenance Proteins.

Authors:  Alessandra De Leo; Abram Calderon; Paul M Lieberman
Journal:  Trends Microbiol       Date:  2019-10-14       Impact factor: 17.079

6.  Antitumor activity of cyclin-dependent kinase inhibitor alsterpaullone in Epstein-Barr virus-associated lymphoproliferative disorders.

Authors:  Takahiro Watanabe; Yoshitaka Sato; H M Abdullah Al Masud; Masahiro Takayama; Hiroki Matsuda; Yuya Hara; Yusuke Yanagi; Masahiro Yoshida; Fumi Goshima; Takayuki Murata; Hiroshi Kimura
Journal:  Cancer Sci       Date:  2019-12-11       Impact factor: 6.716

Review 7.  Epstein-Barr Virus and Multiple Sclerosis.

Authors:  Gunnar Houen; Nicole Hartwig Trier; Jette Lautrup Frederiksen
Journal:  Front Immunol       Date:  2020-12-17       Impact factor: 7.561

8.  Integrative profiling of Epstein-Barr virus transcriptome using a multiplatform approach.

Authors:  Ádám Fülöp; Gábor Torma; Norbert Moldován; Kálmán Szenthe; Ferenc Bánáti; Islam A A Almsarrhad; Zsolt Csabai; Dóra Tombácz; János Minárovits; Zsolt Boldogkői
Journal:  Virol J       Date:  2022-01-06       Impact factor: 4.099

Review 9.  Epigenetic lifestyle of Epstein-Barr virus.

Authors:  Alexander Buschle; Wolfgang Hammerschmidt
Journal:  Semin Immunopathol       Date:  2020-03-30       Impact factor: 9.623

10.  Histone Loaders CAF1 and HIRA Restrict Epstein-Barr Virus B-Cell Lytic Reactivation.

Authors:  Yuchen Zhang; Chang Jiang; Stephen J Trudeau; Yohei Narita; Bo Zhao; Mingxiang Teng; Rui Guo; Benjamin E Gewurz
Journal:  mBio       Date:  2020-10-27       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.